Fresenius Kabi has announced the launch of Clofarabine Injection, a generic version of Genzyme’s Clolar, to treat relapsed or refractory acute lymphoblastic leukemia in patients aged 1 to 21.
Clofarabine, a purine nucleoside metabolic inhibitor, is indicated as treatment following at least two prior regimens.
“Continuing to develop critical and accessible medicines for all patients is fundamental to the Fresenius Kabi mission of ‘caring for life’,” said Fresenius Kabi CEO, John Ducker.
Clofarabine Injection is supplied as single-dose vials containing 20mg per 20mL of clofarabine.
For more information call 847-550-5751 or visit Fresenius-kabi.us.